Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jupiter Neurosciences, Inc. (JUNS)
USD0.18
+0.00 (+0.28%)
US NASDAQ Healthcare Biotechnology
Address
1001 North US HWY 1 33477
Jupiter, FL, US
Jupiter, FL, US
CEO
Christer Rosen
Website
jupiterorphan.com
IPO
2022-01-18
CIK 1679628 ISIN US48208B2034
Description
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current name in August 2021 and is headquartered in Jupiter, Florida.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.18
+0.00 (+0.28%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
7M
Beta
1.69
Float Shares
16.59M
Free Float %
45.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.29% | -0.59% | -22.69% | -39.62% | -73.39% | -66.86% | -39.96% | -93.84% | -93.84% | -93.84% | -93.84% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.18
Ratings Trend (MoM)
100% Bullish
| Rating | 2025-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-20.46
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-194.8% Q1'26: -26.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-39,179.2% Q1'26: -7,678.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-39,359.9% Q1'26: -10,524.3% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +2,506.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+20.3% Q1'26: +6.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.62× Q1'26: -0.62× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|
| Revenue |
—
|
21.8K
est: 75.0K (-70.9%)
|
12.13M
12.13M – 12.13M
+16,076.0% YoY
|
7.36M
7.36M – 7.36M
-39.4% YoY
|
| EBITDA |
-2.19M
|
-8.58M
est: -15.0K (-57,096.3%)
|
-2.43M
-2.43M – -2.43M
-16,077.1% YoY
|
-1.47M
-1.47M – -1.47M
+39.4% YoY
|
| EBIT |
-2.19M
|
-8.58M
est: -15.0K (-57,096.3%)
|
-2.43M
-2.43M – -2.43M
-16,077.1% YoY
|
-1.47M
-1.47M – -1.47M
+39.4% YoY
|
| Net Income |
-2.44M
est: -1.73M (-41.3%)
|
-8.64M
est: -9.00M (+4.0%)
|
2.08M
2.08M – 2.08M
+123.1% YoY
|
-9.00M
-9.00M – -9.00M
-533.3% YoY
|
| SGA |
2.60M
|
6.84M
est: 4.98M (+37.2%)
|
806.37M
806.37M – 806.37M
+16,076.0% YoY
|
489.06M
489.06M – 489.06M
-39.4% YoY
|
| EPS |
-0.08
est: -0.06 (-41.3%)
|
-0.25
est: -0.26 (+3.8%)
|
0.06
0.06 – 0.06
+123.1% YoY
|
-0.26
-0.26 – -0.26
-533.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-5.78M
OE per share TTM
-0.17
Owner's Yield
-48.54%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
28.7%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
3
Total invested
169.8K
Insider transactions (90d)
0
Beneficial owners (>5%)
4
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Rosén | 13.07M | 39.50% | 13.07M | — | 13.07M | — | IN | States | 2024-11-15 | ↗ |
| 2 | Marshall Hayward | 4.02M | 12.50% | 4.02M | — | 4.02M | — | IN | States | 2024-11-15 | ↗ |
| 3 | Claes Wahlestedt | 3.33M | 10.90% | 3.33M | — | 3.33M | — | IN | States | 2024-11-15 | ↗ |
| 4 | Shaun Brothers | 2.04M | 6.70% | 2.04M | — | 2.04M | — | IN | States | 2024-11-15 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
3
-9 vs prev Q
New positions
3
Closed positions
12
Increased
3
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | VESTOR CAPITAL, LLC | 671.00 -970.3K (-99.9%) | 990.0K -719.0K (-42.1%) | 0.00% -2.851 pp | 0.07% -0.041 pp | USD1.76 -42.0% | 2 qtrs — |
| 2 | VANGUARD GROUP INC | 248.9K +33.1K (+15.3%) | 253.9K -126.0K (-33.2%) | 0.73% +0.097 pp | 0.00% +0.000 pp | USD1.66 -38.6% | 2 qtrs — |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 132.6K +28.8K (+27.8%) | 135.3K -47.4K (-26.0%) | 0.39% +0.085 pp | 0.00% +0.000 pp | USD1.60 -36.3% | 2 qtrs — |
| 4 | YORKVILLE ADVISORS GLOBAL, LP | 131.9K +131.9K (+100.0%) | 134.5K +134.5K (+100.0%) | 0.39% +0.388 pp | 0.08% +0.085 pp | USD1.02 +0.0% | 1 qtrs NEW |
| 5 | ALLEN CAPITAL GROUP, LLC | 30.0K +30.0K (+100.0%) | 30.6K +30.6K (+100.0%) | 0.09% +0.088 pp | 0.00% +0.003 pp | USD1.02 +0.0% | 1 qtrs NEW |
| 6 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 29.3K +29.3K (+100.0%) | 29.9K +29.9K (+100.0%) | 0.09% +0.086 pp | 0.00% +0.000 pp | USD1.02 +0.0% | 1 qtrs NEW |
| 7 | NORTHERN TRUST CORP | 25.3K +527.0 (+2.1%) | 25.9K -17.8K (-40.8%) | 0.07% +0.002 pp | 0.00% +0.000 pp | USD1.74 -41.4% | 2 qtrs — |
| 8 | XTX TOPCO LTD | 21.5K +6.4K (+42.4%) | 21.9K -4.6K (-17.4%) | 0.06% +0.019 pp | 0.00% -0.001 pp | USD1.54 -33.8% | 2 qtrs — |
| 9 | JANE STREET GROUP, LLC | 14.5K +2.1K (+16.7%) | 14.7K -7.1K (-32.4%) | 0.04% +0.006 pp | 0.00% +0.000 pp | USD1.65 -38.2% | 2 qtrs — |
| 10 | RUSSELL INVESTMENTS GROUP, LTD. | 3.0K +3.0K (+100.0%) | 3.1K +3.1K (+100.0%) | 0.01% +0.009 pp | 0.00% +0.000 pp | USD1.02 +0.0% | 1 qtrs NEW |
| 11 | — | 1.0K +1.0K (+100.0%) | 1.0K +1.0K (+100.0%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD1.02 +0.0% | 1 qtrs NEW |
| 12 | BANK OF AMERICA CORP /DE/ | 142.00 +21.0 (+17.4%) | 145.00 -68.0 (-31.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.64 -37.8% | 2 qtrs — |
| 13 | CITIGROUP INC | — -12.4K (-100.0%) | — -21.9K (-100.0%) | 0.00% -0.037 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 14 | UBS GROUP AG | — -4.1K (-100.0%) | — -7.2K (-100.0%) | 0.00% -0.012 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 11 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 32.0K | 0.05% |
| 2 | Vanguard Total Stock Market ETF VTI | 0.00% | 8.5K | 0.03% |
| 3 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 18.06 | 0.03% |
| 4 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 49.59 | 0.17% |
| 5 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 3.66 | 0.17% |
| 6 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 18.80 | 0.22% |
| 7 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 10.39 | 0.22% |
| 8 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 4.00 | 0.22% |
| 9 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 0.46 | 0.22% |
| 10 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 0.05 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
5
Sells
0
Shares acquired
4.4K
Shares disposed
—
Cash buys
5.00
Cash sales
—
Net activity
+4,350
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-07-02 | Silva Alison D. | Officer | A-Award | A | Stock Option (right to buy) | 255,320 | 1.19 | 303.8K | 255,320 | D | ↗ |
| 2025-07-02 | Elmasri Saleem | Officer | A-Award | A | Stock Option (right to buy) | 102,128 | 1.19 | 121.5K | 102,128 | D | ↗ |
| 2025-07-01 | Silva Alison D. | Director / Officer | P-Purchase | A | Common Stock | 250 | 1.03 | 258.50 | 112,777 | D | ↗ |
| 2025-07-01 | ROSEN CHRISTER | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 3,100 | 1.02 | 3.2K | 11,078,892 | D | ↗ |
| 2025-06-30 | Silva Alison D. | Director / Officer | P-Purchase | A | Common Stock | 100 | 1.02 | 101.68 | 111,177 | D | ↗ |
| 2025-06-30 | ROSEN CHRISTER | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 700 | 1.03 | 721.00 | 11,072,792 | D | ↗ |
| 2025-06-27 | Silva Alison D. | Director / Officer | P-Purchase | A | Common Stock | 250 | 1.05 | 262.50 | 111,077 | D | ↗ |
| 2025-06-27 | ROSEN CHRISTER | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 166 | 1.06 | 175.96 | 11,067,642 | D | ↗ |
| 2025-06-02 | Silva Alison D. | Director / Officer | M-Exempt | A | Common Stock | 110,227 | 0.00 | — | 110,227 | D | ↗ |
| 2025-06-02 | ROSEN CHRISTER | Director / Officer / 10% Owner | M-Exempt | A | Common Stock | 497,396 | 0.00 | — | 10,591,406 | D | ↗ |
| 2025-06-02 | Elmasri Saleem | Officer | M-Exempt | A | Common Stock | 66,293 | 0.00 | — | 66,239 | D | ↗ |
| 2025-01-22 | Weis Holger | Director | M-Exempt | A | Common Stock, par value $0.0001 per share | 10,781 | 0.00 | — | 10,781 | D | ↗ |
| 2025-01-22 | Brady Allison W | Director | M-Exempt | A | Common Stock, par value $0.0001 per share | 21,750 | 0.00 | — | 21,750 | D | ↗ |
| 2024-11-08 | Wahlestedt Claes Robert | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 2,757,353 | D | ↗ |
| 2024-11-08 | Rosen Alexander Gustaf Erik | Officer | — | — | Common Stock | 0 | 0.00 | — | 356,250 | D | ↗ |
| 2024-11-08 | ROSEN CHRISTER | Director / Officer / 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 10,094,010 | D | ↗ |
| 2024-11-08 | Hayward Marshall A. | Director / Officer | — | — | Common Stock | 0 | 0.00 | — | 1,980,882 | D | ↗ |
| 2023-12-18 | Weis Holger | Director | — | — | Stock option (right to buy) | 8,730 | 1.33 | 11.6K | 0 | D | ↗ |
| 2023-12-18 | Wahlestedt Claes Robert | 10% Owner | — | — | Stock option (right to buy) | 7,752 | 1.33 | 10.3K | 0 | D | ↗ |
| 2023-12-18 | Silva Alison D. | Director / Officer | — | — | Restricted stock unit | 110,228 | 0.00 | — | 0 | D | ↗ |
| 2023-12-18 | Rosen Alexander Gustaf Erik | Officer | — | — | Restricted stock unit | 164,554 | 0.00 | — | 0 | D | ↗ |
| 2023-12-18 | ROSEN CHRISTER | Director / Officer / 10% Owner | — | — | Restricted stock unit | 497,397 | 0.00 | — | 0 | D | ↗ |
| 2023-12-18 | Kampf Julie B. | Director | — | — | Stock option (right to buy) | 8,434 | 1.33 | 11.2K | 0 | D | ↗ |
| 2023-12-18 | Hemmerly Nicholas H. | Director | — | — | Stock option (right to buy) | 9,724 | 1.33 | 12.9K | 0 | D | ↗ |
| 2023-12-18 | Hayward Marshall A. | Director / Officer | — | — | Restricted stock unit | 389,794 | 0.00 | — | 0 | D | ↗ |
| 2023-12-18 | Elmasri Saleem | Officer | — | — | Stock option (right to buy) | 22,320 | 1.33 | 29.7K | 0 | D | ↗ |
| 2023-12-18 | Brady Allison W | Director | — | — | Restricted stock unit | 78,000 | 0.00 | — | 0 | D | ↗ |
| 2022-07-22 | ROSEN CHRISTER | Director / Officer / 10% Owner | — | — | Restricted stock award | 474,070 | 0.00 | — | 0 | D | ↗ |
| 2022-07-21 | Wahlestedt Claes Robert | 10% Owner | — | — | Restricted stock award | 46,620 | 0.00 | — | 0 | D | ↗ |
| 2022-07-21 | Rosen Alexander Gustaf Erik | Officer | — | — | Restricted stock award | 96,608 | 0.00 | — | 0 | D | ↗ |
| 2022-07-21 | Hayward Marshall A. | Director / Officer | — | — | Restricted stock award | 399,402 | 0.00 | — | 0 | D | ↗ |
| 2021-08-09 | Weis Holger | Director | — | — | Convertible notes | 8,928 | 2.80 | 25.0K | 0 | D | ↗ |
| 2021-08-09 | Brady Allison W | Director | — | — | Convertible notes | 18,000 | 2.80 | 50.4K | 0 | D | ↗ |
| 2020-02-01 | Wahlestedt Claes Robert | 10% Owner | — | — | Stock option (right to buy) | 135,000 | 0.88 | 118.8K | 0 | D | ↗ |
| 2020-02-01 | Rosen Alexander Gustaf Erik | Officer | — | — | Stock option (right to buy) | 168,750 | 0.80 | 135.0K | 0 | D | ↗ |
| 2020-02-01 | ROSEN CHRISTER | Director / Officer / 10% Owner | — | — | Stock option (right to buy) | 392,613 | 0.88 | 345.5K | 0 | D | ↗ |
| 2020-02-01 | Hayward Marshall A. | Director / Officer | — | — | Stock option (right to buy) | 393,750 | 0.80 | 315.0K | 0 | D | ↗ |
| 2019-01-24 | Wahlestedt Claes Robert | 10% Owner | — | — | Stock option (right to buy) | 84,938 | 0.74 | 62.9K | 0 | D | ↗ |
| 2019-01-24 | Rosen Alexander Gustaf Erik | Officer | — | — | Stock option (right to buy) | 569,775 | 0.74 | 421.6K | 0 | D | ↗ |
| 2019-01-24 | ROSEN CHRISTER | Director / Officer / 10% Owner | — | — | Stock option (right to buy) | 811,812 | 0.74 | 600.7K | 0 | D | ↗ |
| 2018-12-13 | Silva Alison D. | Director / Officer | — | — | Stock option (right to buy) | 225,000 | 0.80 | 180.0K | 0 | D | ↗ |
| 2016-01-01 | Wahlestedt Claes Robert | 10% Owner | — | — | Stock option (right to buy) | 225,000 | 0.01 | 2.3K | 0 | D | ↗ |
| 2016-01-01 | Hayward Marshall A. | Director / Officer | — | — | Stock option (right to buy) | 225,000 | 0.01 | 2.3K | 0 | D | ↗ |
Executive team
Top executives
EBIT / Employee
-21.4K
Shares Outstanding
36.28M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Christer Rosén Chairman of the Board and Chief Executive Officer | 134.8K | — | — | — | — | 19.3K | 154.1K | 0.00% | ↗ |
| 2 | 2024 | Alison Silva Chief Business Officer and President | 96.3K | — | — | — | — | 42.3K | 138.5K | 0.00% | ↗ |
| 3 | 2024 | Saleem Elmasri Chief Financial Officer | 127.0K | — | — | — | — | — | 127.0K | 0.00% | ↗ |
| 4 | 2024 | Marshall Hayward Chief Scientific Officer | 107.8K | — | — | — | — | — | 107.8K | 0.00% | ↗ |
| 5 | 2024 | Alexander Rosén Chief Administration Officer | 77.0K | — | — | — | — | 26.7K | 103.7K | 0.00% | ↗ |
| 6 | 2023 | Christer Rosén Chairman of the Board and Chief Executive Officer | — | — | 661.5K | 771.6K | — | 4.3K | 1.44M | 99.70% | ↗ |
| 7 | 2023 | Marshall Hayward Chief Scientific Officer | — | — | 518.4K | 604.6K | — | 18.6K | 1.14M | 98.37% | ↗ |
| 8 | 2023 | Saleem Elmasri Chief Financial Officer | — | — | 88.2K | 690.3K | — | — | 778.5K | 100.00% | ↗ |
| 9 | 2023 | Alison Silva Chief Business Officer and President | — | — | 146.6K | 363.5K | — | 35.0K | 545.1K | 93.58% | ↗ |
| 10 | 2023 | Alexander Rosén Chief Administration Officer | — | — | 218.9K | 255.2K | — | 27.3K | 501.4K | 94.56% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Christer Rosen | Co-Founder, Chief Executive Officer & Chairman of the Board | 671.4K | male |
| Alison D. Silva | President, Chief Business Officer & Director | 376.8K | female |
| Alexander Rosen | Co-Founder & Chief Administrative Officer | 339.7K | male |
| Saleem Elmasri | Chief Financial Officer & Secretary | 312.0K | male |
| Marshall Hayward | Co-Founder, Chief Scientific Officer & Director | 242.5K | — |
| Claes Wahlestedt | Co-Founder, Co-Chairman of Scientific Advisory Board & Consulting Chief Medical Officer | — | — |
| Shaun Brothers | Co-Founder Member of Scientific Advisory Board & Consulting Vice President of Science Research | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for JUNS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
